• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Lexaria Bioscience Corp (NQ: LEXX )

    2.230 -0.050 (-2.19%)
    Streaming Delayed Price Updated: 2:25 PM EST, Nov 5, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Lexaria Bioscience Corp

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    29 30 Next >
    TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Looking to Tap into Various Growing Markets
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    Lexaria Bioscience Corp. (NASDAQ: LEXX) Partners with the National Research Council of Canada for DehydraTECH-GLP-1 Mode of Action Investigation
    Via Investor Brand Network
    Lexaria Bioscience Corp. (NASDAQ: LEXX) Partners with the National Research Council of Canada for DehydraTECH-GLP-1 Mode of Action Investigation
    Via CannabisNewsWire
    Lexaria Bioscience Corp. (NASDAQ: LEXX) Set to Extend Operational Runway to 2025 Following Warrant Exercise and Issuance
    Via Investor Brand Network
    Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 Study
    Via ACCESSWIRE
    Lexaria Awarded New Patents
    Lexaria receives new patents in the fields of epilepsy and anti-viral agents 
    Via TheNewswire.com
    Topics Intellectual Property
    Exposures Intellectual Property
    Lexaria Awarded New Patents
    Via ACCESSWIRE
    Lexaria Bioscience Corp. (NASDAQ: LEXX) Set to Extend Operational Runway to 2025 Following Warrant Exercise and Issuance
    Via CannabisNewsWire
    CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Begins Dosing of Human Pilot Study No. 2, GLP-1-H24-2
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Begins Dosing of Human Pilot Study No. 2, GLP-1-H24-2
    Via CannabisNewsWire
    Topics Intellectual Property
    Exposures Intellectual Property
    Lexaria Begins Dosing of Its Second GLP-1 Human Pilot Study
    Via ACCESSWIRE
    Lexaria Bioscience Corp. (NASDAQ: LEXX) Targeting the Massive Type 2 Diabetes and Obesity Markets with its DehydraTECH(TM) Technology
    Via Investor Brand Network
    Lexaria Bioscience Corp. (NASDAQ: LEXX) Targeting the Massive Type 2 Diabetes and Obesity Markets with its DehydraTECH(TM) Technology
    Via CannabisNewsWire
    CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Launches New Research Program to Evaluate DehydraTECH-GLP-1 Drugs
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Launches New Research Program to Evaluate DehydraTECH-GLP-1 Drugs
    Via CannabisNewsWire
    Topics Intellectual Property
    Exposures Intellectual Property
    Lexaria Announces New Research Program to Evaluate Mode of Action and Performance of DehydraTECH-GLP-1 Drugs
    Via ACCESSWIRE
    CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces $4.7M Warrant Exercise Agreement
    Via CannabisNewsWire
    Topics Intellectual Property
    Exposures Intellectual Property
    CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces $4.7M Warrant Exercise Agreement
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    Lexaria to Receive $4.7 Million Gross Proceeds in Warrant Exercise and Issuance
    Via ACCESSWIRE
    Lexaria Bioscience Corp. (NASDAQ: LEXX) Marks GLP-1 Study Milestone with Ethics Review Board Approval
    Via Investor Brand Network
    Lexaria Bioscience Corp. (NASDAQ: LEXX) Marks GLP-1 Study Milestone with Ethics Review Board Approval
    Via CannabisNewsWire
    12 Health Care Stocks Moving In Tuesday's After-Market Session
    Via Benzinga
    CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Receives Approval to Commence Human Pilot Study Evaluating GLP-1, DehydraTECH
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Receives Approval to Commence Human Pilot Study Evaluating GLP-1, DehydraTECH
    Via CannabisNewsWire
    Topics Intellectual Property
    Exposures Intellectual Property
    Lexaria Bioscience Corp. (NASDAQ: LEXX) Grows Global Patent Portfolio to 41; Maintains Focus on GLP-1 Clinical Studies for 2024
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    Lexaria Bioscience Corp. (NASDAQ: LEXX) Bolsters C-Suite with New CFO Appointment
    Via Investor Brand Network
    Lexaria Bioscience Corp. (NASDAQ: LEXX) Bolsters C-Suite with New CFO Appointment
    Via CannabisNewsWire
    LEXX Stock Earnings: Lexaria Bioscience Beats EPS for Q2 2024
    LEXX stock results show that Lexaria Bioscience beat analyst estimates for earnings per share the second quarter of 2024. 
    Via InvestorPlace
    TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Focusing on ‘Overwhelming Interest’ for GLP-1 Applications of DehydraTECH(TM)
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    Lexaria Bioscience Corp. (NASDAQ: LEXX) Hires Contract Research Organization to Perform Important GLP-1 Human Pilot Study
    Via Investor Brand Network
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    29 30 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.